Clarivate Epidemiology’s coverage of emerging vaccines comprises epidemiological estimates of eligible populations in the major mature pharmaceutical markets (United States, France, Germany, Italy, Spain, United Kingdom, and Japan). We report the eligible population rate per 1,000 persons for each country, as well as annualized counts projected to the national population.
All populations are forecast over a period of 20 years for the major mature pharmaceutical markets covered in this report.
All forecast data are available on the Clarivate Insights Platform in tabular format, with options to download to MS Excel. All populations are accompanied by a comprehensive description of the methods and data sources used, with hyperlinks to external sources. A summary evidence table generated as part of our systematic review of the epidemiological literature is provided for full transparency into research and methods.
The full list of the populations that we forecast for emerging vaccines are as follows:
- HBV vaccine-eligible population, pediatrics.
- HBV vaccine-eligible population, adolescents.
- HBV vaccine-eligible population, adults.
- HBV vaccine newly eligible population, pediatrics.
- HBV vaccine newly eligible population, adolescents.
- HBV vaccine newly eligible population, adults.
- HPV vaccine-eligible population, adolescent males.
- HPV vaccine-eligible population, adolescent females.
- HPV vaccine-eligible population, adult males.
- HPV vaccine-eligible population, adult females.
- HPV vaccine newly eligible population, adolescent males.
- HPV vaccine newly eligible population, adolescent females.
- HPV vaccine newly eligible population, adult males.
- HPV vaccine newly eligible population, adult females.
- Influenza vaccine total eligible population.
- Pneumococcal vaccine total eligible population.
- Pneumococcal vaccine newly eligible population.
- Shingles vaccine total eligible population.
- Shingles vaccine newly eligible population.
- Meningococcal ACWY vaccine total eligible population.
- Meningococcal ACWY vaccine newly eligible population.
- Meningococcal B vaccine total eligible population.
- Meningococcal B vaccine newly eligible population.
- RSV vaccine-eligible population, pediatrics.
- RSV vaccine-eligible population, adults.
- RSV vaccine-eligible population, maternal.
- RSV vaccine newly eligible population, pediatrics.
- RSV vaccine newly eligible population, adults.
- RSV vaccine newly eligible population, maternal.
Note: Coverage may vary by country.
- Emerging Vaccines - Epidemiology - Mature Markets
- Introduction
- Key Findings
- HPV Vaccine-Eligible Population per 1,000 Adult Females in 2021 and 2041
- HPV Vaccine-Eligible Population per 1,000 Adult Females in 2021 and 2041
- HPV Vaccine-Eligible Population per 1,000 Adult Males in 2021 and 2041
- HPV Vaccine-Eligible Population per 1,000 Adult Males in 2021 and 2041
- HPV Vaccine-Eligible Population per 1,000 Adolescent Females in 2021 and 2041
- HPV Vaccine-Eligible Population per 1,000 Adolescent Females in 2021 and 2041
- HPV Vaccine-Eligible Population per 1,000 Adolescent Males in 2021 and 2041
- HPV Vaccine-Eligible Population per 1,000 Adolescent Males in 2021 and 2041
- HBV Vaccine-Eligible Population per 1,000 children in 2021 and 2041
- HBV Vaccine-Eligible Population per 1,000 children in 2021 and 2041
- HBV Vaccine-Eligible Population per 1,000 Adolescents in 2021 and 2041
- HBV Vaccine-Eligible Population per 1,000 Adolescents in 2021 and 2041
- HBV Vaccine-Eligible Population per 1,000 Adults in 2021 and 2041
- HBV Vaccine-Eligible Population per 1,000 Adults in 2021 and 2041
- RSV Vaccine-Eligible Population per 1,000 Adults in 2021 and 2041
- RSV Vaccine-Eligible Population per 1,000 Adults in 2021 and 2041
- RSV Maternal-Vaccine-Eligible Population per 1,000 Women in 2021 and 2041
- RSV Maternal-Vaccine-Eligible Population per 1,000 Women in 2021 and 2041
- RSV Vaccine-Eligible Population per 1,000 Children in 2021 and 2041
- RSV Vaccine-Eligible Population per 1,000 Children in 2021 and 2041
- Shingles Vaccine-Eligible Population per 1,000 People in 2021 and 2041
- Shingles Vaccine-Eligible Population per 1,000 People in 2021 and 2041
- Influenza Vaccine-Eligible Population per 1,000 People in 2021 and 2041
- Influenza Vaccine-Eligible Population per 1,000 People in 2021 and 2041
- Pneumococcal Vaccine-Eligible Population per 1,000 People in 2021 and 2041
- Pneumococcal Vaccine-Eligible Population per 1,000 People in 2021 and 2041
- Meningococcal B Vaccine-Eligible Population per 1,000 People in 2021 and 2041
- Meningococcal B Vaccine-Eligible Population per 1,000 People in 2021 and 2041
- Meningococcal ACWY Vaccine-Eligible Population per 1,000 People in 2021 and 2041
- Meningococcal ACWY Vaccine-Eligible Population per 1,000 People in 2021 and 2041
- Epidemiology Data
- Methods
- Reference Materials
Jagriti Prasad
Jagriti Prasad, M.P.H., is an associate epidemiologist at Clarivate. Prior to joining the company, she worked on a research project exploring trends in a rare cancer and its subtype using data spanning 44 years in the largest cancer registry of northern England (NRYPMDR). She obtained her M.P.H. from Newcastle University in the United Kingdom and her B.D.S. from Manipal University in India.
Mudasir Khan, M.P.H.
Mudasir Khan, M.P.H., Manager, Epidemiology. Before joining Clarivate, Mr. Khan worked as a team lead at IKS Health, an organization that works on patient-level healthcare data management. His areas of expertise at the Clarivate epi team are oncology and psychiatry. He holds a master’s degree in public health from the Tata Institute of Social Sciences in Mumbai.